ClinicalTrials.gg
TerminatedNCT03060980Updated Mar 7, 2019

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

A Phase 3 interventional study of ITCA 650 20/60 mcg/day and Empagliflozin (oral) in Diabetes Mellitus, Type 2, sponsored by Intarcia Therapeutics. Terminated at 101 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-07.

Sponsored by Intarcia Therapeutics · Phase 3, Interventional, and Treatment

Why this study was terminated
Decision by Sponsor

From the registry’s dates

  • Primary completion was Jan 2018, 8 years 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2019.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
31st of 130
245 · median 79
Started
2017
with 13 others
Phase 3
28 of 130
1 open now
Registered
50th of 130
by date

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 14 that started in 2017, is one of 28 in phase 3, and was the 50th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A Phase 3b, open-label, randomized, multicenter, efficacy, safety, and tolerability study of ITCA 650 compared to Empagliflozin and to Glimepiride, as add-on therapy to Metformin in patients with Type 2 diabetes.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of T2D 3 months prior to the Screening Visit.
  • (BMI) between ≥25 to ≤45 kg/m2 at the Screening Visit.
  • Glycosylated (HbA1c) ≥7.5 and ≤10.5%. 5. 6. On a stable (3 months prior to the Screening Visit) treatment regimen of metformin monotherapy of ≥1500 mg/day).

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes.
  • Prior participation in a clinical study involving ITCA 650.
  • Treatment with any GLP-1 receptor agonist (eg, liraglutide, exenatide) within 6 months prior to Screening.
  • History or evidence, within the last 6 months prior to the Screening Visit, of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke.
  • History or evidence of acute or chronic pancreatitis.
  • History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2.
  • Treatment of medications that affect GI motility.
  • History of to exenatide, empagliflozin, or glimepiride or to one of its .
  • Women that are pregnant, lactating, or planning to become pregnant.
  • Chronic (>10 consecutive days) treatment with systemic within 8 weeks prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Experimental: Group 1

    ITCA 650 20/60 mcg/day

    Drug: ITCA 650 20/60 mcg/day

  • Experimental
    Experimental: Group 2

    Empagliflozin 10 mg/day and 25 mg/day

    Drug: Empagliflozin (oral)

  • Experimental
    Experimental: Group 3

    Glimepiride 1-6 mg/day

    Drug: Glimepiride (oral)

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction in glycosylated hemoglobin A1c

    To determine whether ITCA 650 is non-inferior either to empagliflozin or to glimepiride in reducing glycosylated hemoglobin A1c (HbA1c) in patients with T2D following 65 weeks of treatment and 4 weeks of post treatment follow up.

    Time frame: Randomization to 69 weeks

  2. Reduction in weight

    To determine whether ITCA 650 is non-inferior either to empagliflozin or to glimepiride in reducing weight in patients with T2D following 65 weeks of treatment and 4 weeks of post treatment follow up.

    Time frame: Randomization to 69 weeks

07

Study locations

101 sites
  • Fountain Hills Family Practice, P.C.
    Fountain Hills, Arizona 85268, United States
  • Thomas C. Lenzmeier, M.D., P.C.
    Glendale, Arizona 85308, United States
  • Family Practice Specialists
    Phoenix, Arizona 85018, United States
  • Central Phoenix Medical Center
    Phoenix, Arizona 85020, United States
  • Fiel Family and Sports Medicine
    Tempe, Arizona 85283, United States
  • Arizona Community Physicians
    Tucson, Arizona 85712, United States
  • Orange Grove Family Practice
    Tucson, Arizona 85741, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Radiant Research
    Carlsbad, California 92008, United States
  • Research Center of Fresno, Inc.
    Fresno, California 93726, United States
  • Marin Endocrine Care and Research, Inc.
    Greenbrae, California 94904, United States
  • National Research Institute
    Huntington Park, California 90255, United States
  • National Research Institute
    Los Angeles, California 91402, United States
  • Catalina Research Institute
    Montclair, California 91710, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Center for Clinical Trials of Sacramento, Inc.
    Sacramento, California 95816, United States
  • Denver VA Medical Center
    Aurora, Colorado 80045, United States
  • Radiant Research
    Centennial, Colorado 75115, United States
  • Colorado Springs Health Partners - East
    Colorado Springs, Colorado 80922, United States
  • Columbine Family Practice
    Littleton, Colorado 80128, United States
  • Nature Coast Clinical Reseaerch - Crystal River
    Crystal River, Florida 34429, United States
  • Indago Research and Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Research Institure of South Florida
    Miami, Florida 33173, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Palm Harbor Medical Associates
    Palm Harbor, Florida 34684, United States
  • Andres Patron, D.O., P.A
    Pembroke Pines, Florida 33026, United States
  • South Broward Research
    Pembroke Pines, Florida 33027, United States
  • Primary Care Research Group
    Atlanta, Georgia 30312, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Michigan Avenue Internists
    Chicago, Illinois 60604, United States
  • Medical and Procedural Specialists
    Skokie, Illinois 60077, United States
  • HSHS Medical Group DIabetes Research
    Springfield, Illinois 62711, United States
  • Community Hospital of Anderson and Madison County, Inc.
    Anderson, Indiana 46011, United States
  • Clinical Research Advantage
    Evansville, Indiana 47225, United States
  • American Health Network of Indiana, LLC
    Franklin, Indiana 46131, United States
  • American Health Network of Indiana, LLC
    New Albany, Indiana 47150, United States
  • Heartland Research Associates, LLC
    Augusta, Kansas 67010, United States
  • Overland Park Surgical Specialists, LLL dba College Park Family Care Center
    Overland Park, Kansas 66210, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67205, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Maine Research Associates
    Auburn, Maine 04210, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Radiant Research, Inc.
    Edina, Minnesota 55435, United States
  • Ehrhardt Clinical Research, LLC
    Belton, Missouri 64012, United States
  • HealthCare Research Network
    Hazelwood, Missouri 63042, United States
  • Mercury Street Medical Group
    Butte, Montana 59701, United States
  • Skyline Medical Center
    Elkhorn, Nebraska 68022, United States
  • Nevada Family Care
    Henderson, Nevada 89047, United States
  • Palm Research Center, Inc.
    Las Vegas, Nevada 89148, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Scott Research Center
    Laurelton, New York 11413, United States
  • American Health Research
    Charlotte, North Carolina 28207, United States
  • Medication Management, LLC
    Greensboro, North Carolina 27408, United States
  • Down East Medical Associates, PA
    Morehead City, North Carolina 28557, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Radiant Research
    Akron, Ohio 44311, United States
  • Sentral Clinical Research Services, LLC
    Cincinnati, Ohio 45236, United States
  • Canyon Medical Center, LLC
    Columbus, Ohio 43213, United States
  • Aventiv Research
    Columbus, Ohio 43231, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Wells Institute for Health Awareness
    Kettering, Ohio 45429, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • Oklahoma City Clinic - Midwest City
    Midwest City, Oklahoma 73110, United States
  • Intend Research
    Norman, Oklahoma 73069, United States
  • Oklahoma City Clinic - Central
    Oklahoma City, Oklahoma 73104, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Clinical Research Institute of Southern Oregon, PC
    Medford, Oregon 97504, United States
  • Harleysville Medical Associates
    Harleysville, Pennsylvania 19438, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Preferred Primary Care Phys Inc
    Pittsburgh, Pennsylvania 15243, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Holston Medical Group, P.C.
    Kingsport, Tennessee 37660, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • DCT-AACT, LLC dba Discovery Clinical Trials
    Austin, Texas 78758, United States
  • Dallas Diabetes and Endocrine Center
    Dallas, Texas 75230, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • Global Medical Research
    DeSoto, Texas 75115, United States
  • Juno Research
    Houston, Texas 77004, United States
  • PCP for Life - -Tidwell
    Houston, Texas 77093, United States
  • Sante Clinical Research
    Kerrville, Texas 78028, United States
  • Health Texas Research Institute
    San Angelo, Texas 78228, United States
  • Panacea Clinical Research
    San Antonio, Texas 78228, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Victorium Clinical Research Ltd.
    San Antonio, Texas 78230, United States
  • MacGregor Medical Center
    San Antonio, Texas 78240, United States
  • Crossroads Clinical Research, LLC
    Victoria, Texas 77901, United States
  • Ericksen Research and Development, LLC
    Clinton, Utah 84015, United States
  • Radiant Research
    Murray, Utah 84123, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Sound Healthcare
    Port Orchard, Washington 98366, United States
  • Bailey Clinic
    Red Deer, Alberta T466V7, Canada
  • CookMed Research
    Victoria, British Columbia V8V 4A1, Canada
  • Milestone Research
    London, Ontario N5W 6A2, Canada
  • Bluewater Clinical Research Group
    Sarnia, Ontario N7T 4X3, Canada

Showing the first 100 of 101 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Jan 2018, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2017
First posted
Feb 23, 2017
StartActual
Mar 3, 2017
Primary completionActual
Jan 26, 2018
CompletionActual
Jan 26, 2018
Results delay requested
Feb 28, 2019
Last update
Mar 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03060980
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Mar 3, 2017
Primary completion
Jan 26, 2018
Completion
Jan 26, 2018
Last update
Mar 7, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Glimepiride

Start the discussion